Mobile

A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) wi...

Update Il y a 4 ans
Reference: EUCTR2009-017197-21

A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) with Overactive Bladder (OAB) Protocol for Phase I Study of solifenacin succinate suspension Single ascending dose PK study

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the PK of solifenacin succinate suspension after single-dose administration at different dose levels in children and adolescents with OAB.

Inclusion criteria

  • Overactive Bladder

Links